Table 3. Correlation between baseline inflammatory indicators and clinical response (ORR, DCR) in 88 patients with advanced gastric cancer.
| Responses group | Non-ORR N (%) | ORR N (%) | χ2 (ORR) | P value (ORR) | Non-DCR N (%) | DCR N (%) | χ2 (DCR) | P value (DCR) |
|---|---|---|---|---|---|---|---|---|
| NLR | 11.719 | 0.001 | 6.214 | 0.013 | ||||
| <2.84 | 3 (6.7) | 42 (93.3) | 2 (4.4) | 43 (95.6) | ||||
| ≥2.84 | 17 (39.5) | 26 (60.5) | 11 (25.6) | 32 (74.4) | ||||
| NER | 0.000 | 0.999 | 0.000 | 0.999 | ||||
| <86.72 | 13 (21.0) | 49 (79.0) | 9 (14.5) | 53 (85.5) | ||||
| ≥86.72 | 4 (20.0) | 16 (80.0) | 3 (15.0) | 17 (85.0) | ||||
| PLR | 5.523 | 0.019 | 3.412 | 0.065 | ||||
| <82.23 | 0 (0.0) | 10 (100.0) | 0 (0.0) | 10 (100.0) | ||||
| ≥82.23 | 20 (25.6) | 58 (74.4) | 13 (16.7) | 65 (83.3) | ||||
| LMR | 8.351 | 0.004 | 1.739 | 0.187 | ||||
| <2.35 | 13 (39.4) | 20 (60.6) | 7 (21.2) | 26 (78.8) | ||||
| ≥2.35 | 7 (12.7) | 48 (87.3) | 6 (10.9) | 49 (89.1) | ||||
| HALP | 4.512 | 0.034 | 0.456 | 0.499 | ||||
| <31.17 | 16 (32.0) | 34 (68.0) | 9 (18.0) | 41 (82.0) | ||||
| ≥31.17 | 4 (10.5) | 34 (89.5) | 4 (10.5) | 34 (89.5) | ||||
| SII | 3.382 | 0.066 | 0.487 | 0.485 | ||||
| <814.8 | 9 (16.4) | 46 (83.6) | 7 (12.7) | 48 (87.3) | ||||
| ≥814.8 | 11 (33.3) | 22 (66.7) | 6 (18.2) | 27 (81.8) |
Note:
Abbreviation used: ORR, objective response rate; DCR, disease control rate; N, number of patients; NLR, neutrophil count to lymphocyte count ratio; NER, neutrophil count to eosinophil count ratio; PLR, platelet count to lymphocyte count ratio; LMR, lymphocyte count to monocyte count ratio; HALP, the hemoglobin, albumin, lymphocyte and platelet score; SII, systemic immune-inflammation index.